Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T14:26:01.738Z.
Calculation as of: 2026-10-06T14:26:01.738Z.
Quote observation: 2026-10-06T14:25:04.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 3328ed161ff00c537a80d7dceb604f662f1c22c4e65cb57a824bf36ce3bbbe60
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$843.53M
PS Ratio
29.36
TTM Avg
20.29
3Y Avg
47.07
5Y Avg
47.07
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Corvus Pharmaceuticals, Inc. (CRVS) | $865.29M | N/A | N/A | N/A | N/A |
| Arbutus Biopharma Corp (ABUS)vs › | $885.96M | 4.88 | 37.06 | 52.92 | 39.21 |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $843.53M | 29.36 | 20.29 | 47.07 | 47.07 |
| Bioventus Inc. (BVS)vs › | $890.64M | 1.53 | 1.18 | 0.98 | 0.92 |
| Beta Bionics, Inc. (BBNX)vs › | $835.01M | 7.02 | 8.02 | 9.17 | 9.17 |
| Alumis Inc. (ALMS)vs › | $825.62M | 111.60 | 174.59 | 129.38 | 129.38 |
| Apnimed, Inc. (APMD)vs › | $818.83M | N/A | N/A | N/A | N/A |
| Jade Biosciences, Inc. (JBIO)vs › | $817.92M | N/A | N/A | N/A | N/A |
| HealthStream, Inc. (HSTM)vs › | $917.50M | 2.86 | 2.39 | 2.83 | 2.81 |
| Ardelyx, Inc. (ARDX)vs › | $809.02M | 1.79 | 3.32 | 5.97 | 11.95 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-04 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-12 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-07 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-06 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
